Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.16
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.32 +0.87%
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.16). Revenue for the quarter came in at $24.84 million versus the consensus estimate of $10.22 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Lucid reports Q2 output, names new CFO and five other leaders
- Six Flags names Mark Pauls as chief operating officer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
